Results 241 to 250 of about 404,123 (293)
Some of the next articles are maybe not open access.
Immunotoxins and recombinant toxins in the treatment of solid carcinomas
The American Journal of Surgery, 1993Cancer remains the second most common cause of death in our society, and advanced disease is often refractory to surgical, chemotherapeutic, and radiologic interventions. One novel approach to cancer treatment involves targeting a cytotoxic agent to a cancer cell. Immunotoxins have been developed that contain a potent toxin (either Pseudomonas exotoxin,
C P, Theuer, I, Pastan
openaire +2 more sources
Production and Purification of Recombinant Toxins
2019Recombinant expression of toxins enables us to produce adequate quantities of these proteins which can be used to perform experiments at molecular, cellular, and behavioral levels. Furthermore, toxins can be edited by using simple molecular biology methods when producing them recombinantly.
openaire +2 more sources
Recombinant toxins in haematologic malignancies and solid tumours
Expert Opinion on Investigational Drugs, 1998Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli.
openaire +2 more sources
Comparison of wild type with recombinant Clostridium difficile toxin A
Microbial Pathogenesis, 2005Toxins A and B from Clostridium difficile are single-chain proteins of 308,000 and 270,000 Da, respectively. They possess transferase activity to monoglucosylate proteins of the Rho GTPase family whereby Rho, Rac, and Cdc42 are the canonical substrates.
Ralf, Gerhard +5 more
openaire +2 more sources
Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen
Medical Microbiology and Immunology, 1992The epidermolytic (exfoliative) toxins produced by Staphylococcus aureus cause epidermolysis and skin blistering. In addition, they have been implicated to belong to the group of T lymphocyte stimulating molecules known as "superantigens". Here we show that recombinant epidermolytic toxin A produced in S.
B, Fleischer, C J, Bailey
openaire +2 more sources
Recombinant toxins for the treatment of cancer.
Current opinion in molecular therapeutics, 2003Recombinant toxins are proteins made by genetic engineering consisting of a toxin fused to a ligand which binds selectively to a target cell. Recombinant toxins used for cancer treatment generally contain either a growth factor or a recombinant fragment of a monoclonal antibody fused to a truncated bacterial toxin, derived either from Pseudomonas ...
openaire +1 more source
Recombinant diphtheria toxin fragments
International Journal of Biochemistry, 1989GELFAND DAVID H +2 more
openaire +3 more sources
Engineering of recombinant toxins and toxin-specific antibodies
Toxicon, 1997F. Ducancel +5 more
openaire +1 more source